According to Adaptimmune Therapeutics's latest financial reports the company's current revenue (TTM ) is S$0.23 Billion. In 2023 the company made a revenue of S$79.61 Million an increase over the revenue in the year 2022 that were of S$36.39 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.